Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study is to demonstrate the superiority in efficacy of the GK530G (fixed combination of
CD0271 0.1% and CD1579 2.5%) versus each of the monads (CD0271 0.1% and CD1579 2.5%) in the
treatment of acne vulgaris for up to 12 weeks, in the Japanese patients.
Phase:
Phase 3
Details
Lead Sponsor:
Galderma R&D
Treatments:
Adapalene Adapalene, Benzoyl Peroxide Drug Combination Benzoyl Peroxide